Aims Obesity is associated with the development of atrial fibrillation (AF), and both obesity and AF are independently associated with the development of heart failure with preserved ejection fraction. We tested the hypothesis that sleep apnea (SA) would have a body mass index (BMI) independent association with adverse left ventricular (LV) remodeling and clinical outcomes in patients with AF and preserved LV function.
Methods and results
From 720 consecutive patients with AF, 403 patients without myocardial disease (preserved LV function) were identified and followed up for 3.3 ± 1.5 years. The primary outcome was a combination of all-cause mortality/heart failure hospitalization. Left ventricular mass and LV mass-to-volume ratio were higher in patients with SA and obesity (P b .0001 for all). Body mass index (β per log = .47; P b .0001) and SA (β = .05; P = .045) were independently associated with LV mass index. Patients with treated SA had a lower LV mass index (but not LV mass-to-volume ratio) compared with untreated (P = .002). In a best overall multivariable model, SA therapy (β = −.129; P = .001) and BMI (β per log = .373; P = .0007) had opposing associations with LV mass index. Sleep apnea (hazard ratio [HR] = 2.94; P = .0004) and BMI (HR per 1 kg/m 2 = 1.08; P = .004) were associated with clinical outcome in unadjusted analysis. Only SA was associated with clinical outcome in a best overall multivariable model (HR = 2.14; P = .02).
Conclusion Sleep apnea and obesity are independently associated with adverse LV remodeling and clinical outcomes in patients with preserved LV function, whereas continuous positive airway pressure therapy is associated with a beneficial effect on LV remodeling. Research investigating SA therapies in patients at high risk for LV remodeling and heart failure is warranted.
(Am Heart J 2014;167:620-6.)
Approximately half of patients with newly diagnosed heart failure (HF) are classified as HF with preserved ejection fraction (HF-pEF). Contemporary treatments for HF-pEF remain limited, and therapy is directed primarily at underlying comorbidities. Multiple associations with HF-pEF exist, including obesity, hypertension, diabetes, and atrial fibrillation (AF). There is a complex interplay between these risk factors; obesity is associated with the development of AF, 1 and both obesity and AF are independently associated with the development of HFpEF. 2 Furthermore, animal and small physiologic studies demonstrate a dose-dependent effect of obesity on myocardial remodeling, 3 suggesting an independent role for obesity and obesity-related cardiovascular illness in the pathogenesis of incident HF.
Among contributors to obesity-related heart disease, sleep apnea (SA) appears to play a role in integrating factors critical to the development of HF-pEF, including AF, [4] [5] [6] systemic hypertension, 7 vascular stiffness, 8 and left ventricular hypertrophy. 9 Interventions such as continuous positive airway pressure (CPAP) are associated with improvement in diastolic function and reduction in recurrent AF, 4,10-15 both contributors to the progression to HF. Given the influence of AF on HF-pEF, investigating a possible body mass index (BMI) independent association of SA with adverse left ventricular (LV) structure and function and clinical outcome in patients with AF may establish a rationale for more aggressive SA screening and treatment.
To address the independent contributions of SA and obesity on LV structure in AF, we performed a prospective observational cohort study of patients referred for cardiac magnetic resonance (CMR) imaging before AF ablation. Given their potential for additive effect on LV structure, we hypothesized that both BMI and SA would be associated with LV mass and concentric LV remodeling (by LV mass-to-volume ratio). Furthermore, we investigated the association of both obesity and SA on all-cause mortality and HF hospitalization.
Methods

Study population
We studied 403 patients undergoing CMR before pulmonary vein isolation at the Brigham and Women's Hospital between September 2005 and June 2011. Patients with evidence of prior myocardial infarction (MI) (defined by clinical evidence of MI per history, electrocardiographic criteria, or late gadolinium enhancement by CMR) were excluded. Given our focus on HFpEF, patients with reduced left ventricular ejection fraction (LVEF) by CMR (LVEF b50%) were excluded. All patients had either paroxysmal AF (AF terminating spontaneously b7 days after onset) or persistent AF (AF N7 days) as an indication for AF ablation. Heart failure was defined by clinical history in the medical record by a cardiologist (TGN) blinded to all imaging variables. Obesity was defined as a BMI ≥30 kg/m 2 . The presence or absence of SA was prospectively determined (and blinded to the results of the CMR) as part of the institutional screening process before anesthesia. All patients diagnosed with SA had undergone polysomnography. The diagnosis of SA reflected the sleep study criteria recommended by the American Academy of Sleep Medicine. 16 Data regarding the extent of use of CPAP were obtained from each patient from follow-up phone interviews. Therapy with CPAP was defined as N4 hours of continuous CPAP per night on average. The human subjects' research review committee of our institution approved the study protocol (See Figure) .
CMR protocol
Cardiac magnetic resonance imaging was used to measure LV end-diastolic mass, end-systolic and diastolic volumes, and LVEF using standard techniques. Cardiac magnetic resonance was performed on either a 1.5-or 3.0-T system (SignaHDxt; General Electric Healthcare, Waukesha, WI and Tim Trio; Siemens, Erlangen, Germany, respectively), using electrocardiographic or pulse gating during breath hold. The CMR protocol consisted of cine steady-state free precession imaging for cardiac function (typical repetition time; 3.4 ms and echo time; 1.2 ms and in-plane spatial resolution; 1.6 × 2 mm) and mass, pulmonary vein anatomy imaging, and late gadolinium enhancement imaging, as has been described by our laboratory. 17 Cine images were obtained in 8 to 14 matching short axis (8-mm thick; 0-mm spacing) and 3 radial long-axis planes with full ventricular coverage. Left ventricular function and mass were quantified by Simpson's technique. We indexed LV mass and volumes to height 2.7 , as previously reported. 18 Images were analyzed using Mass Research (Leiden University Medical Center, Leiden, Belgium) or CMR42 (Circle Cardiovascular Imaging, Calgary, Canada).
Adjudication of clinical events
Patients were followed up postprocedure at 3-to 6-month intervals via clinic visits. Our end point was a composite of allcause mortality and HF hospitalization. We assessed mortality via the Social Security Death Index and electronic medical records. When medical records provided insufficient follow-up information, the patient and the primary provider was contacted. Heart failure hospitalization was confirmed by a review of all medical records from hospitalizations occurring after the index CMR scan, including clinical notes and radiography.
Statistical analysis
Continuous data are presented as median and interquartile range (IQR) stratified by obesity, with intergroup comparison using the Wilcoxon rank sum test. Categorical covariates were compared with χ 2 testing. To measure the association of BMI and LV remodeling, we calculated Spearman rank-order correlation coefficients between BMI and parameters of LV structure and compared LV structural parameters by SA status using Wilcoxon rank sum testing. Given potential confounding by factors related both to obesity and SA, we constructed multivariable linear regression models for height-indexed LV mass and LV mass-to-volume ratio (dependent variables), adjusted for age, gender, hypertension, diabetes, and prior coronary revascularization, with inclusion of SA (as a binary covariate) and BMI. In the subset of patients with SA (n = 75), we performed additional stepwise multivariable linear regression modeling (model entry P b .05; model retention P b .05) using identical covariates as above, including the presence of SA therapy to identify an association of SA therapy with LV remodeling indices. Height-indexed LV parameters and BMI were log-transformed to establish normality. Finally, to measure the association of BMI and SA with all-cause mortality/HF hospitalization, we used univariable and multivariable Cox proportional hazards regression modeling out to maximum follow-up. We conducted a best overall, backward multivariable Cox model (model entry P b .05; model retention P b .05), including all covariates used in univariable models. Proportional hazards assumptions were assessed for each covariate. KaplanMeier methods were used to estimate censored event-free survival for the primary and secondary outcomes stratified by obesity and SA status separately, with comparison of survival by the log-rank test. A 2-tailed P value of b .05 was considered significant, and statistical analysis was performed in SAS version 9.3 (SAS Institute Inc, Cary, NC).
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Results
Clinical and demographic characteristics
Baseline characteristics are shown in Table I . Overall, 290 (72%) patients were male, with a median age of 57 years. All patients had a history of AF, with 138 (34%) having paroxysmal AF and 267 (66%) with persistent AF. Cardiometabolic risk was prevalent in this population, including hypertension (47%), diabetes (14%), and SA (19%). Obesity was present in 148 patients (37%), with a median BMI 33.8 kg/m 2 in the obese (vs 26.5 kg/m 2 in nonobese; P b .0001). Obese patients had a greater median systolic blood pressure (131 vs 125 mm Hg in nonobese; P = .008), more prevalent SA (30% vs 12% in nonobese; P b .0001), and a trend toward more prevalent diabetes (19% vs 12% in nonobese; P = .06). History of prior HF was similar across obesity strata (20% vs 14% in nonobese; P = .16), as was AF grade (persistent vs paroxysmal), New York Heart Association functional status, or prior revascularization.
Cardiac structure and function
Cardiac magnetic resonance results are shown in Table II . As expected, overall LVEF was preserved (median 60.4; IQR: 56.2-64.3). Obese individuals had a trend toward higher LV end-diastolic volume index (P = .05), a higher LV mass (P b .0001) and LV mass-to-volume ratio (P b .0001), greater maximal left atrial volume (P = .009), and trend toward higher right ventricular end-diastolic volume index (P = .05). Of note, both LVEF and right ventricular ejection fraction were similar between obese and nonobese subjects (P = .62 and .85, respectively).
Independent association of BMI and SA with cardiac structure and LV remodeling
In addition to the differences in cardiac structure and function observed with obesity stratified around 30 kg/ m 2 (Table II) , there were associations between BMI and indexed LV mass (Spearman ρ = 0.50; P b .0001) and LV mass-to-volume ratio (Spearman ρ = 0.23; P b .0001). Similarly, patients with SA had a higher indexed LV mass (median 29.6 g/m 2.7 without SA vs 34.3 kg/m 2.7 with SA; P b .0001) and higher LV mass-to-volume ratio (median 0.85 without SA vs 0.96 with SA; P = .009). However, both SA and obesity were strongly associated with cardiometabolic diseases implicated in LV remodeling (eg, diabetes, hypertension), suggesting the possibility of residual confounding.
Multivariable linear regression models for heightindexed LV mass and LV mass-to-volume ratio (dependent variables), adjusted for well-established risk factors for LV remodeling, 3 with inclusion of SA (as a binary covariate) and BMI are shown in Table III . In addition to older age (P b .0001) and the presence of diabetes (P = .007), both a higher BMI (P b .0001) and a diagnosis of SA (P = .04) were independently associated with LV mass index. In a separate model for LV mass-to-volume ratio, hypertension (P = .02), diabetes (P = .02), and BMI (P = .01) but not SA, were independently associated with a greater LV mass-tovolume ratio.
Association of SA therapy with LV mass and concentric LV remodeling
Of the 75 patients who had SA, 37 (50%) were receiving CPAP therapy. Relative to those without therapy, patients receiving CPAP were similar in age, BMI, systolic blood pressure, and had no difference in medication, New York Heart Association functional status, history of HF, diabetes, hypertension, or gender. Structurally, patients receiving SA treatment had no difference in LV/right ventricular volumes or ejection fraction. Although LV mass-to-volume ratio was similar by treatment, LV mass index was lower in treated SA relative to untreated SA (37.8 g/m 2.7 vs 31.8 g/m 2.7 ; P = .002). In a best overall multivariable linear regression among patients with SA (n = 75), only SA therapy (β = −.129; P = .001) and BMI (β per log = .373; P = .0007) remained in the model with independent, opposing effects on LV mass index.
Association of BMI and SA with adverse outcomes
Complete follow-up was available for all patients. The mean follow-up in our cohort was 3.3 ± 1.5 years. Kaplan-Meier estimates of event-free survival to 5 years stratified by SA and obesity are shown in the Figure. The overall annual rate of all-cause mortality/HF hospitalization was 3.4% per patient-year (46 events over 1,344 patient-years). The annual event rate was higher in obese versus nonobese individuals (5.1% vs 2.5%/patient-year; P b .0001 by χ 2 ) and in individuals with SA versus those without SA (7.3% vs 2.6%/patientyear; P b .0001).
Sleep apnea (HR = 2.94; 95% CI 1.61-5.35) (P = .0004) and body mass index (HR per 1 kg/m 2 = 1.08; 95% CI 1.03-1.14) (P = .004) were significantly associated with our primary composite end point (Table IV) in addition to clinical risk factors well established to predict cardiovascular risk (eg, age, diabetes, hypertension, history of HF). However, in a backward selection multivariable model, in addition to age, history of HF, the presence of AF, and diabetes, the presence of SA (but not BMI) was associated with an independent 2-fold higher risk of the composite end point (HR = 2.14, 95% CI 1.16-3.98) (P = .02).
Discussion
In a population free of prior MI or LV dysfunction referred for AF ablation, we found that obesity was associated with greater cardiometabolic risk, higher prevalence of SA, and more adverse LV remodeling. The association between LV mass and both BMI and SA remained independent of diabetes, hypertension, and age, whereas BMI (but not SA) was associated with concentric LV remodeling. Furthermore, patients with treated SA had a lower LV mass index relative to the untreated, even after adjustment for BMI, hypertension, diabetes, and other clinical risk factors. These abnormalities in LV structure translated into a higher annual rate of allcause mortality or HF hospitalization for individuals with either obesity or SA. At a mean follow-up N3 years, SA (but not BMI) was independently associated with a N2-fold hazard of all-cause mortality or HF hospitalization, after adjustment for previous HF, age, and diabetes. These results highlight a role for SA independent of BMI, suggesting that targeting SA in addition to weight reduction may mitigate adverse LV remodeling and improve clinical outcome.
Although obesity has been independently associated with SA, HF-pEF, and AF in community-based studies, 1, 2 the independent role for SA in myocardial remodeling is less well studied. Despite the recognition that SA affects myocardial physiology central to HF-pEF, 4, [7] [8] [9] 19 SA remains underappreciated and undertreated: in 1 study, b5% of obese, diabetic patients with clinically significant SA at risk for HF-pEF were treated 1 year after diagnosis. 20 Although earlier studies suggested that obesity and weight reduction were associated with LV mass improvement, 21 more recent studies suggest that SA itself may be independently harmful to the ventricle 10 . In addition, some reports have demonstrated a weight and metabolic syndrome independent association of SA with LV structure. 22, 23 Our results extend the current literature on SA, obesity, and cardiac remodeling in a large group of patients with AF at risk for HF-pEF by establishing the independent association of both SA and BMI with LV mass, a prognostically important index of LV remodeling. 24 The cross-sectional association with LV mass suggests the potential for benefit with CPAP therapy to reverse ventricular remodeling. In the largest study of cardiac structure with CMR in SA, Colish et al 25 investigated 47 patients with SA undergoing CPAP therapy, finding a reduction in body surface area-indexed LV mass (159 ± 12 g/m 2 -141 ± 8 g/m 2 ) at 6 months after CPAP initiation with sustained benefits to 1 year. Left ventricular mass regression occurred coordinately with improvements in pulmonary, biatrial, and biventricular function, suggesting a global benefit of CPAP on myocardial structure and function. Our cross-sectional results in a group of 75 patients with SA add to these results by demonstrating (1) a higher LV mass in those individuals with SA not receiving CPAP and (2) independent and opposing effects of SA therapy and BMI on LV mass after multivariable adjustment. Collectively, these findings highlight the distinct effects of BMI and SA on LV remodeling and suggest the possibility of significant reverse remodeling by SA therapy regardless of BMI. The relevance of SA across BMI-and potential impact of SA therapy in obese patients-must be tied to clinical outcomes. Specifically, whether SA itself poses a risk independent of obesity remains unknown, especially within populations at high risk for HF-pEF. We addressed this question by selecting a referral population at high risk for incident HF (ie, established AF) and used CMR to exclude patients with established myocardial disease. We found that while both BMI and SA were associated with all-cause mortality or HF hospitalization, only presence of SA, diabetes, history of HF, and age were selected in a multivariable model as independent correlates of outcome. This result suggests that obesity-related illness-SA and diabetes-may be more important than obesity itself. Thus, further study on the impact of obesity independent of its associated comorbidities may be warranted.
The results of our study should be viewed in the context of its design. This was a cross-sectional analysis of patients referred for AF ablation, limiting the generalizability of our findings. However, CMR results allowed us to select carefully a population free from myocardial disease, still at high residual risk for progressive LV remodeling and HF. We did not perform a formal sleep study on all patients referred for pulmonary vein isolation. This approach likely yielded a significant underestimation in the prevalence of SA, which is estimated to be close to 50% in this population. 5 We did not measure apnea-hypopnea indices in our cohort, limiting an assessment of the association of SA with remodeling or outcome, although we still observed significant relationships with these end points. Finally, our CMR protocol did not capture emerging parameters relevant to subclinical LV remodeling in obesity and SA (eg, diffuse myocardial fibrosis, arterial stiffness). 26 Given the links between obesity and myocardial fibrosis, 27 identification of patients with prevalent tissue-level remodeling to target intensity, duration, and mode of therapy is an important emerging area of investigation.
In conclusion, in patients with AF, preserved LV function without prior MI, both obesity and SA are associated with indices of LV remodeling, independent of traditional risk factors for LV remodeling. Patients with SA treated with CPAP have less myocardial hypertrophy relative to those who remain untreated, even after adjustment for BMI. Sleep apnea is a strong and independent predictor of all-cause mortality or HF hospitalization in patients with AF. Future prospective investigation of SA across BMI with and without therapy with a comprehensive assessment of cardiac and vascular structure and function is warranted.
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